Breast CarcinomaNCT05978128
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
A study testing Health Education, Health Promotion and Education and Patient Navigation in people with Breast Carcinoma and Lung Carcinoma, run by Jonsson Comprehensive Cancer Center at 1 site in United States.
Trial summary
This clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants. Imaging-based cancer screening is utilized with variable frequency. Read more about this study
- Who is it for?
- Ages 40 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Breast Carcinoma, Lung Carcinoma
- What is being tested?
- Health Education, Health Promotion and Education and Patient Navigation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 800 participants
- Where
- 1 siteUnited States
- Study dates
- 28 Jul 2023to 30 Sep 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age:
- Breast screening > 40
- Lung screening 50-80
- Male (M) or Female (F)
- Current, former, or never smokers
- Close family or friend with smoking history (in or out of state)
Who cannot join
- Age:
- Breast screening < 40
- Lung screening < 50 or > 80
- Persons who had previously received a diagnosis of lung cancer, had hemoptysis, or had an unexplained weight loss of more than 6.8 kg (15 lb) in the preceding year will also be excluded
- Persons with an active cancer
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095
Ashley E. Prosper, 310-825-0958, APROSPER@MEDNET.UCLA.EDU
Ashley E. Prosper
About this study
Official title: Utilizing Spheres of Influence to Increase Cancer Screening: Empowering Community Health Advocates
This clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants. Imaging-based cancer screening is utilized with variable frequency. Breast cancer screening with mammography has been widely accepted and is commonly used among eligible women. Lung screening with computed tomography scans is poorly used, despite the potential to decrease deaths from lung cancer. There are many reasons lung screening isn't being used when compared to breast screening, such as smoking stigma and fear, along with a lack of awareness of lung screening. By conducting this trial, researchers want to assess the effectiveness of advocates and supporters of breast and lung screening, and to learn about the psychological barriers to cancer screening, identifying those that are unique to lung screening.
Read the detailed description
PRIMARY OBJECTIVES:
- Determine the number of patients undergoing breast screening who are eligible to participate in lung screening.
II. Determine whether patients currently participating in cancer screening (breast OR lung) are successful as "cancer screening advocates." III. Determine whether laypersons who are aware of screening (including those who accompany friends and family members to their screening appointments) are successful as "cancer screening advocates." IV. Identify knowledge base and psychological barriers to screening through surveys of potential screening participants.
OUTLINE:
Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study.
After completion of study intervention, participants are followed up yearly for up to 3 years.
- Conditions
- Breast Carcinoma, Lung Carcinoma
- Being tested
- Health Education, Health Promotion and Education, Patient Navigation, Survey Administration
- Medical subject headings
- Breast Neoplasms, Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Health EducationBehavioural
Access electronic patient portal with educational material
Health Promotion and EducationOther
Receive materials on breast/lung cancer screening
Patient NavigationBehavioural
Also called Patient Navigator Program
Interact with a patient navigator
Survey AdministrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Screening (electronic patient portal, patient navigation) | Experimental | Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study. Receives: Behavioral: Health Education; Other: Health Promotion and Education; Behavioral: Patient Navigation; Other: Survey Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Increased rates of lung and breast cancer screening adherence
By following up with patients over the defined study period and assessing whether they obtained an incidence screen completed at one-year +/- 3 months from the recommended time. Will also measure the rates of survey completion by consented participants, the number of clicks and time spent reviewing educational materials, and the number of new participants who contacted the program through a referral by another participant.
Measured: Up to 3 years
Secondary outcomes (1)
Success of "sphere of influence" model
Considered successful if increased lung cancer screening referrals are a direct result of women receiving screening mammograms inviting and educating friends and family about lung cancer screening.
Measured: Up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2023
- Study start28 Jul 2023
- Primary completion30 Sep 2028 (estimated)
- Study completion30 Sep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CarcinomaStudies of the same condition, open and under way.
- More trials run by Jonsson Comprehensive Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 800 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ashley E Prosper, Principal investigator, UCLA / Jonsson Comprehensive Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05978128
- Sponsor's protocol ID
- 22-000947
- Other IDs
- NCI-2023-04133
- Status last verified
- Nov 2025
- First submitted
- 28 Jul 2023
- Last updated
- 10 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Utilizing Spheres of Influence to Increase Cancer Screening: Empowering Community Health Advocates
- ClinicalTrials.gov ID
- NCT05978128
- Acronym / sponsor ID
- 22-000947
- Conditions
- Breast Carcinoma, Lung Carcinoma
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 800 participants (estimated)
- Lead sponsor
- Jonsson Comprehensive Cancer CenterUniversity, hospital or other
- Study start
- 28 Jul 2023 (actual)
- Primary completion
- 30 Sep 2028 (estimated)
- Study completion
- 30 Sep 2029 (estimated)
- First posted
- 7 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants. Imaging-based cancer screening is utilized with variable frequency. Breast cancer screening with mammography has been widely accepted and is commonly used among eligible women. Lung screening with computed tomography scans is poorly used, despite the potential to decrease deaths from lung cancer. There are many reasons lung screening isn't being used when compared to breast screening, such as smoking stigma and fear, along with a lack of awareness of lung screening. By conducting this trial, researchers want to assess the effectiveness of advocates and supporters of breast and lung screening, and to learn about the psychological barriers to cancer screening, identifying those that are unique to lung screening.
Detailed description
PRIMARY OBJECTIVES:
- Determine the number of patients undergoing breast screening who are eligible to participate in lung screening.
II. Determine whether patients currently participating in cancer screening (breast OR lung) are successful as "cancer screening advocates." III. Determine whether laypersons who are aware of screening (including those who accompany friends and family members to their screening appointments) are successful as "cancer screening advocates." IV. Identify knowledge base and psychological barriers to screening through surveys of potential screening participants.
OUTLINE:
Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study.
After completion of study intervention, participants are followed up yearly for up to 3 years.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Screening (electronic patient portal, patient navigation) | Experimental | Behavioral: Health Education, Other: Health Promotion and Education, Behavioral: Patient Navigation, Other: Survey AdministrationParticipants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study. |
Who may qualify
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age:
- Male (M) or Female (F)
- Current, former, or never smokers
- Close family or friend with smoking history (in or out of state)
Key exclusion criteria (5 listed)
- Age:
- Persons who had previously received a diagnosis of lung cancer, had hemoptysis, or had an unexplained weight loss of more than 6.8 kg (15 lb) in the preceding year will also be excluded
- Persons with an active cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Health EducationAccess electronic patient portal with educational material | Behavioural | Screening (electronic patient portal, patient navigation) |
| Health Promotion and EducationReceive materials on breast/lung cancer screening | Other | Screening (electronic patient portal, patient navigation) |
| Patient NavigationAlso: Patient Navigator ProgramInteract with a patient navigator | Behavioural | Screening (electronic patient portal, patient navigation) |
| Survey AdministrationAncillary studies | Other | Screening (electronic patient portal, patient navigation) |
Primary outcome
Increased rates of lung and breast cancer screening adherence
Time frame: Up to 3 years
By following up with patients over the defined study period and assessing whether they obtained an incidence screen completed at one-year +/- 3 months from the recommended time. Will also measure the rates of survey completion by consented participants, the number of clicks and time spent reviewing educational materials, and the number of new participants who contacted the program through a referral by another participant.
1 secondary outcome
Success of "sphere of influence" model
Time frame: Up to 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Nov 2025.
Related trials for Breast Carcinoma
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, United States
Ashley E Prosper principal investigator
UCLA / Jonsson Comprehensive Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Health Education, Health Promotion and Education and Patient Navigation in people with Breast Carcinoma and Lung Carcinoma, run by Jonsson Comprehensive Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Increased rates of lung and breast cancer screening adherence (time frame: Up to 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Nov 2025.